Agendia

If you're at #NCoBC2026, 🛑 stop by Booth #302 to learn how our genomic tests can provide breast centers with multiple clinically actionable answers for patients with early-stage breast cancer. Within days of diagnosis, MammaPrint + BluePrint can: ✔ Clarify tumor recurrence risk ✔ Show who may safely avoid chemotherapy ✔ Identify who may benefit from endocrine de-escalation ✔ Inform decision-making from neoadjuvant chemo to extended endocrine therapy ✔ Show which patients benefit from the addition of anthracycline and who can forgo #BreastCenters #EarlyStageBreastCancer #PrecisionOncology #GenomicTesting #MammaPrint #BluePrint #InterdisciplinaryBreastCenterConference

Tomorrow: 📅 26 March | 🕧12:30–14:00 |📍 Room 117 at #EBCC15 💫Personalized Breast Cancer Care: Where Genomic Testing Meets Clinical Practice💫 Join us for scientific symposium featuring three expert‑led presentations on the role of genomic testing in breast cancer care: 1️⃣ The Evolving Role of Genomic Assays in Breast Cancer: From Adjuvant to Neoadjuvant - Prof. Dr. Gabe Sonke, Dutch Cancer Institute 2️⃣ Genomic Risk Assessment in Women Over 70: Evidence to Support Personalized Care - Prof. Dr. Hans Wildiers, University Hospital Leuven 3️⃣Refining Systemic Therapy Choices: What Emerging Genomic Evidence Tells Us - William Audeh, MD, MS, CMO, Agendia 🥗 Complimentary lunch for the first 300 arriving attendees at 12:30. Session begins at 12:45. Registration not required, but appreciated: ow.ly/9T9N50Yhm88 Official EBCC15 Sponsored Satellite Symposium #PrecisionMedicine #Symposium

Are you attending #EBCC15 this week? 🤝Visit booth 9 to learn about: ✅ Our recent inclusion in major breast cancer guidelines ✅ How MammaPrint® + BluePrint® provide actionable insight beyond traditional clinicopathologic factors ✅ How genomic risk stratification can help optimize treatment decisions and reduce overtreatment ✅ Real‑world clinical use cases and workflow integration ✅ How our tests can help determine not only if a patient needs chemo, but what type ✅ How to leverage our tests for neoadjuvant decision making #MammaPrint #BluePrint #EBCC

Attending #ASBrS? Don't miss our breakfast symposium featuring Mehran Habibi, MD! 🔗 RSVP today: ow.ly/8aCK50YwyFT At the symposium: ➡️Hear real‑world cases and the latest neoadjuvant data ➡️Learn how MammaPrint® + BluePrint® genomic insights can: ✨Inform neoadjuvant planning ✨Guide surgical decision‑making in early‑stage breast cancer ➡️Discover how surgeons can personalize treatment by leading with tumor biology 📅 Friday, May 1, 2026 🕡 6:30–7:45am (breakfast available at 6:15am) 📍 Room 608–610 | Seattle Convention Center | ASBrS

Attending #ASBrS? Don't miss our breakfast symposium featuring Mehran Habibi, MD! 🔗 RSVP today: ow.ly/zAeN50YwyFQ At the symposium: ➡️Hear real‑world cases and the latest neoadjuvant data ➡️Learn how MammaPrint® + BluePrint® genomic insights can: ✨Inform neoadjuvant planning ✨Guide surgical decision‑making in early‑stage breast cancer ➡️Discover how surgeons can personalize treatment by leading with tumor biology 📅 Friday, May 1, 2026 🕡 6:30–7:45am (breakfast available at 6:15am) 📍 Room 608–610 | Seattle Convention Center | ASBrS

🍀Happy St. Patrick's Day! 💚

Official #EBCC15 Sponsored Satellite Symposium: 💫Personalized Breast Cancer Care: Where Genomic Testing Meets Clinical Practice💫 📅 26 March | 🕧12:30–14:00 |📍 Room 117 If you're attending EBCC15, join us for a scientific symposium featuring three expert‑led presentations on the role of genomic testing in breast cancer care: 1️⃣ The Evolving Role of Genomic Assays in Breast Cancer: From Adjuvant to Neoadjuvant - Prof. Dr. Gabe Sonke, Dutch Cancer Institute 2️⃣ Genomic Risk Assessment in Women Over 70: Evidence to Support Personalized Care - Prof. Dr. Hans Wildiers, University Hospital Leuven 3️⃣Refining Systemic Therapy Choices: What Emerging Genomic Evidence Tells Us - William Audeh, MD, MS, CMO, Agendia 🥗 Complimentary lunch for the first 300 arriving attendees at 12:30. Session begins at 12:45. Registration not required, but appreciated: ow.ly/9T9N50Yhm88 #PrecisionMedicine #Symposium

🧐 Interested in the 5 Genomic Profiles of MammaPrint® + BluePrint®? Join us for an on-demand webinar featuring Dr. William Audeh, MD, MS, as he delves into the five genomic profiles of MammaPrint + BluePrint and the supporting data that addresses key treatment questions for ER+/HER2- early-stage breast cancer. 👉 Watch Now: event.on24.com/wcc/r/5191640/… What You'll Learn: The 5 Genomic Profiles of MammaPrint + BluePrint: • MammaPrint Ultra Low + BluePrint Luminal A • MammaPrint Low + BluePrint Luminal A • MammaPrint High 1 + BluePrint Luminal B • MammaPrint High 2 + BluePrint Luminal B • MammaPrint High 2 + BluePrint Basal 💪Empower yourself with knowledge that can make a difference in treatment decisions!

If you're at #NCoBC, 🛑 stop by Booth #302 to learn how our genomic tests can provide breast centers with multiple clinically actionable answers for patients with early-stage breast cancer. Within days of diagnosis, MammaPrint + BluePrint can: ✔ Clarify tumor recurrence risk ✔ Show who may safely avoid chemotherapy ✔ Identify who may benefit from endocrine de-escalation ✔ Inform decision-making from neoadjuvant chemo to extended endocrine therapy ✔ Show which patients benefit from the addition of anthracycline and who can forgo #BreastCenters #EarlyStageBreastCancer #PrecisionOncology #GenomicTesting #MammaPrint #BluePrint #InterdisciplinaryBreastCenterConference

Official EBCC-15 Sponsored Satellite Symposium: ✨Personalized Breast Cancer Care: Where Genomic Testing Meets Clinical Practice✨ 📅 26 March | 12:30–14:00 |📍 Room 117 If you're at #EBCC15, join us for a scientific symposium featuring three expert‑led presentations on the role of genomic testing in breast cancer care: ➡️ The Evolving Role of Genomic Assays in Breast Cancer: From Adjuvant to Neoadjuvant - Prof. Dr. Gabe Sonke, Dutch Cancer Institute ➡️ Genomic Risk Assessment in Women Over 70: Evidence to Support Personalized Care - Prof. Dr. Hans Wildiers, University Hospital Leuven ➡️Refining Systemic Therapy Choices: What Emerging Genomic Evidence Tells Us - William Audeh, MD, MS, CMO, Agendia 🥗 Complimentary lunch for the first 300 arriving attendees. Registration not required, but appreciated: ow.ly/9T9N50Yhm88 #PrecisionMedicine #Symposium

🎉🌸 Happy International Women’s Day! Today, we celebrate the incredible strength, resilience, and achievements of women around the world. Let’s honor our sisters, mothers, daughters, friends, and trailblazers who inspire us daily. 💪❤️ #IWD2026 #InternationalWomensDay

🎉 Happy Employee Appreciation Day! 🌟 Today, we celebrate the heart of our company – our incredible team! 💼✨ Thank you for your hard work, passion, and dedication. Let’s brighten this day with joy and gratitude! 🥳💖 #EmployeeAppreciationDay

Are you at Miami Breast Cancer Conference this week? 🤝Visit booth 104 and we can discuss: ✅ Recent inclusion in major breast cancer guidelines ✅ How MammaPrint® + BluePrint® provide actionable insight beyond traditional clinicopathologic factors ✅ How genomic risk stratification can help optimize treatment decisions and reduce overtreatment ✅ Real‑world clinical use cases and workflow integration ✅ How our tests can help determine not only if a patient needs chemo, but what type ✅ How to leverage our tests for neoadjuvant decision making #MiamiBreast #MammaPrint #BluePrint #MBCC

Breast surgeons attending #SSO2026 - Visit us at booth 118 to discuss how genomic insights can inform surgical planning earlier. ✨Find out how MammaPrint® + BluePrint® deliver actionable genomic data in just 6 days from core biopsy, helping guide neoadjuvant therapy decisions that support tumor downstaging, surgical de‑escalation, and improved outcomes.✨

Today is Triple-Negative Breast Cancer Day—a day to raise awareness for one of the most challenging breast cancer subtypes. Did you know that MammaPrint® + BluePrint® genomic profiling can identify tumors that behave like triple-negative, even if they appear ER+ under the microscope? This critical insight can change the course of treatment and empower women and their care teams to make more informed decisions. Let’s shine a light on the power of precision medicine. #TNBCDay #EndCancer

At #SABCS2025, Dr. Joyce O’Shaughnessy shared new ACT-TC data from the FLEX Study—and the impact is practice-changing. ✅ MammaPrint® + BluePrint® can help identify which HR+/HER2- early-stage breast cancer patients may benefit from the addition of adjuvant anthracycline therapy ✅ These findings are now recognized in the latest NCCN Guidelines* 🎥 Watch Dr. O’Shaughnessy discuss how this data supports more personalized, biology-driven treatment decisions: ow.ly/NG0m50YmBVF *NCCN Guidelines®: Breast Cancer. (BINV‑N). Version 1.2026. #BreastCancer #PrecisionMedicine #NCCNGuidelines #MammaPrint #BluePrint #Oncology #EarlyBreastCancer #FLEXStudy

📣Did you hear? 📣The NCCN Guidelines®: Breast Cancer. (BINV‑N). Version 1.2026. now include that patients with a MammaPrint High Risk 2 + BluePrint Luminal B tumor benefit from adding anthracycline to a taxane-based adjuvant chemo regimen. When making treatment decisions, you are able to leverage this FLEX Study real-world data to identify those who will benefit from adding anthracycline to a taxane-based adjuvant chemotherapy regimen. And for your patients who have a MammaPrint High Risk 1 tumor, you can consider de-escalating from the addition of anthracycline to their chemo plan. ❓Share in the comments: How do you plan to apply this data in your practice? Read more: agendia.com/agendia-announ… #Chemotherapy #BreastCancer #AC-T #NCCN #FLEXStudy

Breast surgeons attending #SSO2026 — stop by our booth to see how genomic insights can inform surgical planning earlier. ✨Find out how MammaPrint® + BluePrint® deliver actionable genomic data in just 6 days from core biopsy, helping guide neoadjuvant therapy decisions that support tumor downstaging, surgical de‑escalation, and improved outcomes.✨ 📍 Visit Booth #118 to discuss genomics in surgical decision‑making

🤝 Heading to Miami Breast Conference? Make sure Agendia's booth (#104) is on your must‑visit list. When you stop by, you can: ✅ Learn about recent inclusion in major breast cancer guidelines ✅ See how MammaPrint® + BluePrint® provide actionable insight beyond traditional clinicopathologic factors ✅ Learn how genomic risk stratification can help optimize treatment decisions and reduce overtreatment ✅ Connect with our team to discuss real‑world clinical use cases and workflow integration ✅ Learn how our tests can help determine not only if a patient needs chemo, but what type ✅ How to leverage our tests for neoadjuvant decision making Whether you’re looking to refine treatment pathways, better understand tumor biology, or stay current on precision oncology, we’d love to connect. #MiamiBreast #MammaPrint #BluePrint

Black women in the U.S. are 38% more likely to die from breast cancer than white women—a disparity that can’t be explained by access alone. Emerging research shows that tumor biology plays a critical role, with Black women more often affected by aggressive cancers that standard markers may miss. In conversation with @Cure_Today, Dr. William Audeh discusses how genomic subtyping can advance health equity. This Black History Month, advocacy means demanding research, diagnostics, and treatment approaches that recognize biology—and deliver equity. 📺Watch the video: curetoday.com/view/breast-ca… #BlackHistoryMonth #BreastCancerEquity #HealthEquity #CancerAdvocacy #Genomics #PrecisionMedicine